GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Vineet Laboratories Ltd (BOM:543298) » Definitions » Capex-to-Revenue

Vineet Laboratories (BOM:543298) Capex-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Vineet Laboratories Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Vineet Laboratories's Capital Expenditure for the three months ended in Dec. 2023 was ₹0.00 Mil. Its Revenue for the three months ended in Dec. 2023 was ₹326.47 Mil.

Hence, Vineet Laboratories's Capex-to-Revenue for the three months ended in Dec. 2023 was 0.00.


Vineet Laboratories Capex-to-Revenue Historical Data

The historical data trend for Vineet Laboratories's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vineet Laboratories Capex-to-Revenue Chart

Vineet Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Capex-to-Revenue
Get a 7-Day Free Trial - - - - 0.04

Vineet Laboratories Quarterly Data
Mar17 Mar18 Mar19 Mar20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vineet Laboratories's Capex-to-Revenue

For the Chemicals subindustry, Vineet Laboratories's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vineet Laboratories's Capex-to-Revenue Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Vineet Laboratories's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Vineet Laboratories's Capex-to-Revenue falls into.



Vineet Laboratories Capex-to-Revenue Calculation

Vineet Laboratories's Capex-to-Revenue for the fiscal year that ended in Mar. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-76.342) / 2122.933
=0.04

Vineet Laboratories's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 326.47
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vineet Laboratories  (BOM:543298) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Vineet Laboratories Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Vineet Laboratories's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Vineet Laboratories (BOM:543298) Business Description

Traded in Other Exchanges
Address
5-5-160, Malleswari Nilayam, Opposite Vishnu Theatre, Chintalakunta, L.B.Nagar, Hyderabad, TG, IND, 500 074
Vineet Laboratories Ltd Formerly known as Ortin Laboratories Limited, Unit-II is engaged in the business of Pharmaceutical intermediates and Fine chemicals. The products of the companies include Dimethyl phenoxy acetyl chloride, Dimethyl Phenoxy Acetic Acid, Isopropyl-beta-D-thiogalactopyranoside and Nitrophenyl phosphate disodium salt among others. Geographically, the company operates within India and outside India, with a majority of revenue coming from India. The company has one business segment, manufacture of Drug Intermediates & Bulk Dugs.

Vineet Laboratories (BOM:543298) Headlines

No Headlines